UCB selected Gwinnett County, Georgia, for its new U.S. biologics manufacturing facility, a planned 460,000-square-foot campus designed to produce complex biologics 24/7 for the U.S. market. UCB said the project uses a digital-first approach leveraging AI, robotics, and automation and is positioned to strengthen global supply resilience. The company described the facility as part of its broader biologics manufacturing network and cited its track record of FDA approvals, including indication expansions, in the last few years. UCB also put forward economic impact estimates and emphasized local manufacturing and talent strategy. For biotech and CDMO stakeholders, this announcement signals continued investment in capacity for biologics rather than outsourcing-only growth, which can affect supply availability, timelines, and bargaining power across the development-to-commercialization lifecycle. UCB’s move also highlights how digital manufacturing playbooks are becoming part of major site plans, not just platform upgrades inside existing plants.